PubHawk
Lancet June 2017 PMID 28476288

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.

Ajay Gupta, David Thompson, Andrew Whitehouse, Tim Collier, Bjorn Dahlof, Neil Poulter, Rory Collins, Peter Sever

Full text PDF Download social card

Mentions

168
Peak: 2 in Jun 2022
across 5 sources since May 2019

Extended reach

55,580
potential audience

Total likes

45

Video views

3,017

Mentions per month

May 2019 – Apr 2025

Where it's discussed

  • News112 articles
  • Facebook32 posts
  • Blogs14 articles
  • X / Twitter8 posts
  • YouTube2 videos

AI synopsis

What people are saying

The overall tone reflects moderate agreement, with comments highlighting the significance of blinding in accurately assessing adverse events, such as references to hazard ratios and trial phases. Posts show engagement through technical analysis and concern about bias, emphasizing the relevance of rigorous trial designs for clinical safety assessments.

AgreementModerate agreement

Most posts acknowledge the study’s findings, emphasizing that unblinded therapy may overstate adverse events, showing cautious agreement.

InterestModerate interest

Discussions reveal a moderate level of curiosity, with some posts referencing specific data like HR figures and trial details.

EngagementModerate engagement

Several posts analyze the methodology and implications, discussing the relevance of blinding and observational biases.

ImpactModerate impact

The collective discussions suggest recognition of the study’s importance in clinical trial design and drug safety evaluation, indicating a moderate impact.

Abstract in brief

  • The study compares adverse events (AEs) associated with unblinded versus blinded statin therapy, finding that unblinded (nonblind) treatments report more AEs than blinded (e.g., placebo-controlled) trials.
  • In the randomized, double-blind phase of the ASCOT-LLA trial, patients taking atorvastatin showed few adverse events, which were rigorously classified and adjudicated; however, a nonblind extension phase revealed higher rates of certain AEs in patients aware of their treatment.
  • The study emphasizes that awareness of treatment (unblinded therapy) may influence the reporting and incidence of adverse events, highlighting differences between trial phases and the importance of blinding in accurately assessing drug safety.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Fizz-DI＠比較と使い分け-KOJIMA Yushi
@Fizz_DI · X

アトルバスタチン vs プラセボのRCTで報告された筋関連有害事象、ノセボ効果の検証。 二重盲検期：ア2.03% vs プ2.00% →HR=1.03 [95%CI: 0.88-1.21] 盲検解除後：ア1.26% vs プ1.00% →HR=1.41 [95%CI: 1.10-1.79] Lancet.389(10088):2473-2481,(2017) PMID:28476288 https://t.co/SQKCkEyyer

Feb 23, 2024 · 9 likes · 1 share · 34,549 followers View post →
Nicholas Mills
@HighSTEACS · X

@CardiacJoshi @ProfDConnelly @BHFScotland @fi_strachan @DrKate_Miller @ProfDFrancis 260 persons double blind more relevant than unblinded observation in 260 million. Not convinced, try this analysis from ASCOT https://t.co/yHT5R88ITT

Mar 19, 2022 · 5 likes · 3,095 followers View post →
長谷川淳史
@TMS_Japan · X

RT @Fizz_DI: アトルバスタチン vs プラセボのRCTで報告された筋関連有害事象、ノセボ効果の検証。 二重盲検期：ア2.03% vs プ2.00% →HR=1.03 [95%CI: 0.88-1.21] 盲検解除後：ア1.26% vs プ1.00% →HR=1.4…

Feb 23, 2024 · 1 share · 5,340 followers View post →
Toby Richards
@TobyRichardsUEL · X

@MJA_Editor Lancet. 2017 Jun 24;389(10088):2473-2481. doi: 10.1016/S0140-6736(17)31075-9. Epub 2017 May 2. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA):

Feb 6, 2020 · 3,995 followers View post →
UCL Discovery
@ucl_discovery · X

Open Access UCL Research: Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA) https://t.co/KaD5SUJIEM

May 14, 2019 · 2,516 followers View post →
にいやん
@niiyan51 · X

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension... https://t.co/BqxAU7BQoU

Apr 7, 2025 · 1,077 followers View post →

All mentions

にいやん
@niiyan51 · X

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension... https://t.co/BqxAU7BQoU

Apr 7, 2025 · 1,077 followers View post →
長谷川淳史
@TMS_Japan · X

RT @Fizz_DI: アトルバスタチン vs プラセボのRCTで報告された筋関連有害事象、ノセボ効果の検証。 二重盲検期：ア2.03% vs プ2.00% →HR=1.03 [95%CI: 0.88-1.21] 盲検解除後：ア1.26% vs プ1.00% →HR=1.4…

Feb 23, 2024 · 1 share · 5,340 followers View post →
Fizz-DI＠比較と使い分け-KOJIMA Yushi
@Fizz_DI · X

アトルバスタチン vs プラセボのRCTで報告された筋関連有害事象、ノセボ効果の検証。 二重盲検期：ア2.03% vs プ2.00% →HR=1.03 [95%CI: 0.88-1.21] 盲検解除後：ア1.26% vs プ1.00% →HR=1.41 [95%CI: 1.10-1.79] Lancet.389(10088):2473-2481,(2017) PMID:28476288 https://t.co/SQKCkEyyer

Feb 23, 2024 · 9 likes · 1 share · 34,549 followers View post →
にいやん
@niiyan51 · X

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind … https://t.co/BqxAU7BQoU

Dec 31, 2022 · 1,077 followers View post →
Nicholas Mills
@HighSTEACS · X

@CardiacJoshi @ProfDConnelly @BHFScotland @fi_strachan @DrKate_Miller @ProfDFrancis 260 persons double blind more relevant than unblinded observation in 260 million. Not convinced, try this analysis from ASCOT https://t.co/yHT5R88ITT

Mar 19, 2022 · 5 likes · 3,095 followers View post →
いっそくとび
@statandnow · X

スタチンの臨床試験。盲検期間は大丈夫だったが、その後の延長試験で非盲検になったら有意にスタチン群で筋症状が出現していた。Lancet https://t.co/QEhGpsBZPT

May 20, 2020 · 911 followers View post →
Toby Richards
@TobyRichardsUEL · X

@MJA_Editor Lancet. 2017 Jun 24;389(10088):2473-2481. doi: 10.1016/S0140-6736(17)31075-9. Epub 2017 May 2. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA):

Feb 6, 2020 · 3,995 followers View post →
UCL Discovery
@ucl_discovery · X

Open Access UCL Research: Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA) https://t.co/KaD5SUJIEM

May 14, 2019 · 2,516 followers View post →